Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham, today announced progress towards the testing and development of an experimental vaccine called AAVCOVID, a novel gene-based vaccine candidate against SARS-CoV2, the virus that causes COVID-19.
The AAVCOVID vaccine program was developed in the laboratory of Luk H. Vandenberghe, PhD, director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear and Associate Professor of Ophthalmology at Harvard Medical School. It is currently in preclinical development with a plan to begin clinical testing in humans later this year. Mason Freeman, MD, director and founder of the MGH Translational Research Center is leading the efforts to develop the clinical studies intended to establish safety and efficacy of the experimental vaccine.
